 | | Vol. 10.41 – 20 October, 2021 |
| |
|
|
| Scientists sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 small cell lung cancer (SCLC) transcriptomes. They observed greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes.
[Cancer Cell] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| CircIPO11 was highly expressed in hepatocellular carcinoma (HCC) tumor tissues and liver CSCs, and was required for the self-renewal maintenance of liver CSCs to initiate HCC development.
[Molecular Cancer] |
|
|
|
| Human and murine breast CSCs were tested for their production of and response to interleukin-30 by using flow cytometry, confocal microscopy, proliferation and sphere-formation assays, and PCR array.
[Journal For Immunotherapy of Cancer] |
|
|
|
| Lung cancer patient-derived cancer cell and cancer-associated fibroblasts were utilized to mimic the tumor microenvironment and reproduced the stemness properties of CSCs in vitro and developed a high-throughput drug screening platform with phenotypical parameters.
[Theranostics] |
|
|
|
| The genetic manipulation of L1CAM in ovarian carcinoma (OC) cells provided gain and loss-of-function models that were then employed in cell biological assays as well as in vivo tumorigenesis experiments to assess the role of L1CAM in OC cell stemness and in ovarian OSC-driven tumor initiation.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Researchers characterized a novel 12-kDa protein that named musarin, which was purified from Trametes versicolor mushroom extract and showed significant growth inhibition on multiple human colorectal cancer cell lines in vitro.
[Biomedicine & Pharmacotherapy] |
|
|
|
| The extract of A. cherimola showed the highest antioxidant activity and M. oleifera had the highest capacity to enhance the activity of detoxifying enzymes such as glutathione S-transferase and quinone oxidoreductase.
[Biomedicine & Pharmacotherapy] |
|
|
|
| The authors reported on the epidermal growth factor receptor (EGFR)-estrogen receptor beta (ERβ) functional relationship in connection to the aggressiveness and CSC-like characteristics of triple-negative breast cancer cells.
[FEBS Journal] |
|
|
|
| The expression of miR-3065-3p in colorectal cancer and the association of miR-3065-3p expression with prognosis of patients with colorectal cancer were analyzed using TCGA dataset or clinical cases.
[Journal of Translational Medicine] |
|
|
|
| Scientists clarified the significance of autophagy systems of CSCs under stress environments. Four gastric cancer cell line were used.
[Scientific Reports] |
|
|
|
| Investigators evaluated programmed cell death ligand-1 (PD-L1) expression in colorectal CSCs (CCSCs) and non-CCSCs and designed a combination immunotherapy synchronously utilizing PD-L1-chimeric antigen receptor T (CAR)-T cells together with CCSC-dendritic cells vaccine-sensitized T cells for the treatment of colorectal cancer.
[Journal of Cancer] |
|
|
|
|
| LINC00662 can reduce the promoter methylation level of s-adenosylmethionine-dependent hepatocellular carcinoma-promoting genes by regulating the MAT1A/SAM and AHCY/SAH axes, thereby promoting the activation of oncogenes.
[Journal of Cellular Physiology] |
|
|
|
| Scientists discuss the challenges of targeting the Wnt signaling cascade, the safety, efficacy, and therapeutic potential of specific CBP/β-catenin antagonists and a rationale for the pleiotropic effects of CBP/β-catenin antagonists beyond Wnt signaling.
[Expert Opinion On Therapeutic Targets] |
|
|
|
|
| Geron Corporation announced the completion of patient enrollment in the IMerge Phase III clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes.
[NGeron Corporation] |
|
|
|
| Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted positive opinions recommending approval of the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA.
[Merck (BusinessWire, Inc.)] |
|
|
|
|
| November 10 – 19, 2021
Virtual |
|
|
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| University of California Los Angeles – Los Angeles, California, United States |
|
|
|
| | Cancer Research UK Manchester Institute – Manchester, United Kingdom |
|
|
|
| | University of Manitoba – Winnipeg, Manitoba, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
